Mario Corso

Mizuho Securities downgraded Cubist Pharmaceuticals Inc (NASDAQ: CBST) Tuesday from Buy to Neutral and raised its price target from $97 to $102. Analyst Mario Corso noted that after the "market close [Monday] 4 of 5 Cubicin patents were invalidated via court decision, making generics...

Mizuho Securities downgraded Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) from Buy to Neutral and lowered its price target from $37 to $33 in a report issued Friday. On Thursday, Endo Health Solutions Inc (NASDAQ: ENDP) announced it would acquire Auxilium in a $2.6 billion cash and stock...

In a report published Wednesday, Mizuho Securities analyst Mario Corso reiterated a Buy rating on Auxilium Pharmaceuticals (NASDAQ: AUXL), and raised the price target from $33.00 to $37.00. In the report, Mizuho Securities USA noted, “Last night's ENDP bid of $28.10/AUXL share is below 2014 high...

In a report released Tuesday, Mizuho analyst Mario Corso increased the firm's price target on Salix Pharmaceuticals (NASDAQ: SLXP) by 15 percent from $131 to $151. Analysts at Mizuho are bullish on Xifaxan IBS top line data, anticipating approval in the first half of 2015. Salix's...

In a report published Tuesday, Mizuho Securities USA analyst Mario Corso reiterated a Buy rating and $93.00 price target on Questcor Pharmaceuticals (NASDAQ: QCOR). In the report, Mizuho Securities USA noted, “In the wake of today's stock price weakness on short report that FTC will challenge...

In a report published Wednesday, Mizuho Securities analyst Mario Corso upgraded the rating on Cubist Pharmaceuticals (NASDAQ: CBST) from Neutral to Buy, and raised the price target from $50.00 to $77.00. In the report, Mizuho Securities noted, “We are upgrading our rating on CBST shares to Buy...

Avanir Pharmeceuticals (NASDAQ: AVNR) stock plummeted yesterday after Gravity Research said Avanir, “engaged in illegal off-label marketing of Nuedexta,” and recommended a strong Sell. Shares closed at $4.79 on Wednesday, a 13 percent decrease. This was the biggest drop of AVNR in three years...